A hepatitis E vaccine developed by Xiamen Innovax Biotech was granted SFDA approval – the first vaccine approved for hepatitis E anywhere in the world. Innovax worked with researchers at Xiamen University for 14 years to develop the product, which has been supported by grants under China’s 863 Program since 2005. The vaccine was tested in a 100,000 person Phase III trial, whose results were published in The Lancet last year. More details....

Share this with colleagues: